{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T03:56:38Z","timestamp":1767585398291,"version":"3.40.5"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Breast Journal"],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"Introduction. Uncertainty still remains regarding the survival improvement derived from immediate surgery or subsequent surgery in addition to systemic therapy for patients with de novo metastatic breast cancer. The current study aimed to examine the effect of combined treatment administered in different sequences on the survival of these patients. Materials and Methods. We conducted a retrospective cohort study of patients with de novo stage IV breast cancer in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2019. Patients were categorized into 3 groups: (1) systemic therapy without primary surgery, (2) systemic therapy after primary surgery, and (3) systemic therapy before primary surgery. Cumulative incidence curves with Gray\u2019s test were used to compare breast cancer-specific death (BCSD) between groups. Kaplan\u2013Meier curves with the log-rank test were applied to compare overall survival (OS) between groups. A competing risk model and a proportional hazards model were generated to adjust for important prognostic factors. Propensity score matching (PSM) was performed in the primary survival analysis. Stratified analysis was also performed. Results. Patients who underwent systemic therapy after primary surgery and who underwent systemic therapy before primary surgery both showed a significantly reduced risk of BCSD compared to patients who received systemic therapy without primary surgery [subdistribution hazard ratio (SHR): 0.74; 95% confidence interval (CI): 0.69\u20130.79; and \n \n P<\/a:mi>\n <<\/a:mo>\n 0.001<\/a:mn>\n <\/a:math>\n <\/jats:inline-formula>, and SHR: 0.62; 95% CI: 0.56\u20130.67; and \n \n P<\/c:mi>\n <<\/c:mo>\n 0.001<\/c:mn>\n <\/c:math>\n <\/jats:inline-formula>, respectively]. A statistically significant disparity was also noted in OS. In the setting of single-organ metastasis, including the bone, lung, and liver, patients receiving the combination therapy showed an improved prognosis compared with patients receiving systemic therapy without primary surgery. Conclusions. Additional primary tumour excision, whether before or after systemic therapy, may provide survival benefits for patients presenting with de novo metastatic breast cancer, especially for patients with single-organ disease involving the bone, lung, and liver but not the brain. Further investigations mainly focused on these carefully selected candidates are required to improve personalized treatment for metastatic breast cancer.<\/jats:p>","DOI":"10.1155\/2022\/5049445","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T05:35:51Z","timestamp":1661492151000},"page":"1-12","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-8415","authenticated-orcid":true,"given":"Siyi","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Huangpu District, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"volume-title":"SEER Cancer Statistics Review","year":"2021","author":"N. Howlader","key":"2"},{"article-title":"Breast cancer","year":"2022","author":"National Comprehensive Cancer Network","key":"3"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2002.127544"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9527-0"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000002621"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000001302"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02006"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00135-7"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2021.08.686"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000002771"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6494-6"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"year":"2022","key":"14","article-title":"S. E. E. R. datasets and software (R. R. I. D)"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.05.003"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07964-9"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2019.03.006"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651636"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.2226"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0085-x"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1648-2"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2011.06.005"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1809"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08310-2"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3933-6"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6831-9"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24873"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2008.05.018"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.08.007"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-1479"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-2646"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2013.02.002"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/tbj\/2022\/5049445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/tbj\/2022\/5049445.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/tbj\/2022\/5049445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T05:35:55Z","timestamp":1661492155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/tbj\/2022\/5049445\/"}},"subtitle":[],"editor":[{"given":"Taobo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":32,"alternative-id":["5049445","5049445"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5049445","relation":{},"ISSN":["1524-4741","1075-122X"],"issn-type":[{"type":"electronic","value":"1524-4741"},{"type":"print","value":"1075-122X"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}